Peptide receptor radionuclide therapy (PRRT) turns a peptide's binding specificity into a delivery system. The peptide carries a radioisotope to cells that express its receptor; the isotope supplies the effect. It is one of the clearest demonstrations in medicine that a peptide's receptor affinity is a targeting property, not merely a pharmacological one.
The molecule
Lutetium (177Lu) oxodotreotide is a somatostatin analogue — octreotate — linked through a chelator (DOTA) to the beta-emitting isotope lutetium-177, giving the shorthand 177Lu-DOTATATE. Octreotate differs from octreotide at one residue: the C-terminal threoninol is replaced by threonine, which raises its affinity for the somatostatin receptor subtype 2. Lutetium-177 emits beta particles with a maximum tissue range of about 2 mm and has a half-life of about 6.7 days, with gamma emission that allows imaging.
What the evidence shows
The pivotal trial is NETTER-1, a randomised Phase 3 study in advanced midgut neuroendocrine tumours that compared 177Lu-DOTATATE plus long-acting octreotide with high-dose long-acting octreotide alone; it showed a significant improvement in progression-free survival. Longer-term safety data come from the large European ERASMUS registry, which reports myelodysplastic syndrome and acute leukaemia in a small minority of patients alongside renal and other events. Joint EANM, IAEA and SNMMI practical guidance (2026) sets out the current clinical use of somatostatin-receptor-targeted radionuclide therapy.
The UK regulatory picture
The European Commission granted marketing authorisation for lutetium (177Lu) oxodotreotide in September 2017. It is available in the UK, and NICE guidance covers its use within its marketing authorisation for adults with unresectable or metastatic neuroendocrine tumours. Research continues in indications outside the licence — including adolescent patients with gastroenteropancreatic neuroendocrine tumours, and adults with non-gastroenteropancreatic, somatostatin-receptor-positive tumours — where the evidence is thinner.
Why the class matters to a peptide reference
PRRT is the mirror image of the injectable peptides this site covers. In both cases a peptide's structure determines where it binds; the difference is what is attached to it. The somatostatin-receptor affinity that makes octreotide and lanreotide medicines is the same property that makes DOTATATE a vehicle.
Research-use framing
Lutetium (177Lu) oxodotreotide is a prescription radiopharmaceutical, administered in specialist nuclear-medicine services. It has no consumer route and no self-administration application. It appears in this reference as an example of what a licensed peptide can be — and as a reminder that the receptor specificity sometimes marketed as a research attribute is, in a small number of cases, the basis of an authorised medicine.
This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.